Skip to main content

Seer, Inc.

corporate_fare Company Profile

Seer, Inc.

SEER·NASDAQ·Industrial Applications And Services·CIK 0001726445

Our company provides researchers with a platform to study the proteome, which refers to all the proteins in a biological system. Our main product, the Proteograph Product Suite (Proteograph), offers a way to access the proteome in a comprehensive, precise, and scalable manner. This system helps overcome historical limitations in characterizing protein biology at scale, where researchers previously had to choose between in-depth analysis and processing many samples. The Proteograph uses a proprietary engineered nanoparticle (NP) technology. It allows researchers to detect protein isoforms, post-translational modifications (PTMs), and variant peptides at a detailed peptide level, even in complex samples like plasma. This method avoids the need for predefined binding sites, which reduces measurement errors often found in other technologies. The Proteograph Product Suite includes consumable assays, an automation instrument, and data analysis software. Our newest products, the Proteograph ONE assay and the SP200 automation instrument, were launched in May 2025. These innovations have increased throughput by approximately ten-fold compared to our first-generation assay, allowing for the processing of over 1,000 samples per week. The Proteograph generates extensive, high-resolution data per sample and per protein, designed to support scientific discovery driven by artificial intelligence.

Seer, Inc. (NASDAQ:SEER) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 86 items for SEER at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Seer Amends Shareholder Rights Plan, Pays $250K to Settle Lawsuit Amidst Activist Pressure
  • Activist Group Radoff and Torok Increase Stake to 7.6%, Challenges Board's "Poison Pill"
  • Seer, Inc. Authorizes New $25M Share Repurchase Program Amidst Activist Pressure
  • Seer Adopts Poison Pill to Protect NOLs Amidst Activist Investor Pressure
  • Seer Reports Mixed Q4/FY25 Results with Flat 2026 Guidance, Holds Cash Exceeding Market Cap

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$16.58M
Net Income
-$73.6M
Op. Cash Flow
-$44.45M
Free Cash Flow
-$46.24M
Gross Profit
$8.46M
Operating Income
-$77.99M
Cash & Equivalents
$47.28M
Debt / Equity
0.00×
Net Margin
-444.0%
Source: 10-K · filed 2026-04-30 · accession 0001193125-26-197354
$1.38 +1.47% today
52-week range · as of 2026-11-10 $1.38 – $2.38
Market cap
$75.91M
Volume
130.3K (0.8× avg)
3-mo avg 172K
Live data · 2026-11-22 12:49 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed SEER - Filings & News (Page 5)

SEER
Mar 16, 2026, 8:41 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.82
Real-time Price: $1.38 info
Change: -$0.440 (-24%) info
Market Cap: $75.908M info
SEER
Mar 02, 2026, 5:19 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
9
Price at Filing: $1.72
Real-time Price: $1.38 info
Change: -$0.340 (-20%) info
Market Cap: $75.908M info
SEER
Mar 02, 2026, 4:25 PM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $1.73
Real-time Price: $1.38 info
Change: -$0.350 (-20%) info
Market Cap: $75.908M info
SEER
Feb 26, 2026, 4:13 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.81
Real-time Price: $1.38 info
Change: -$0.430 (-24%) info
Market Cap: $75.908M info
SEER
Feb 26, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.81
Real-time Price: $1.38 info
Change: -$0.430 (-24%) info
Market Cap: $75.908M info
SEER
Feb 20, 2026, 10:54 AM EST
Filing Type: SCHEDULE 13D
Importance Score:
9
Price at Filing: $1.96
Real-time Price: $1.38 info
Change: -$0.575 (-29%) info
Market Cap: $75.908M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets